fashion -WSS

fashion

author：entertainment 2025-09-27 22:56:57 - browse：7

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Democrats decry new health bill for going easy on private equity

WSS

Norman Reedus' Daryl Dixon

New lawsuit accuses health insurer Cigna of denying claims in bulk

Plane’s emergency slide plummets from sky, hits Chicago home

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Why some people catch Covid but never get sick

Will the FTC rein in IQVIA's health data empire?

entertainment

fashion

explore

23andMe had bad news about my health. I wish a person had delivered it

What it's like to live with paralysis for one psychologist

Peter Hotez and the public health issue of online harassment

What it's like to live with paralysis for one psychologist

Medicare details structure of new drug price negotiation program

New lawsuit accuses health insurer Cigna of denying claims in bulk

Heart attack and stroke risk calculators need revising

CDC Director Mandy Cohen on transparency, trust, and health

Alkermes shareholders re

Device maker Teleflex to acquire urology company for $600M

focus

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Search called off for baby washed away in Pennsylvania flash flood

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Democrats decry new health bill for going easy on private equity

Roche’s Alnylam deal shows drug firms interested in heart drugs

Biogen says it will cut costs by $700 million, slash 1,000 jobs

entertainment

focus

explore

focus